Acute effects of MDMA, MDA, lysine-MDMA, and lysine-MDA in a randomized, double-blind, placebo-controlled, crossover trial in healthy participants

MDMA acutely produces empathogenic effects such as well-being, trust and connectedness that are thought to support psychotherapy for post-traumatic stress disorder. Its minor active metabolite MDA shares entactogenic properties but differs pharmacologically, exhibiting a higher dopamine-to-serotonin activity ratio and about 10-fold greater potency as a 5-HT2A receptor agonist, which could yield more stimulant-like and psychedelic-like acute effects. Prior human data on MDA are limited and have compared MDA and MDMA across separate studies and samples rather than within the same individuals, leaving uncertainty about their direct comparative pharmacodynamics and pharmacokinetics. Straumann and colleagues designed a within-subject, double-blind, randomized, placebo-controlled crossover trial to compare acute subjective, autonomic, endocrine and pharmacokinetic responses to equimolar doses of MDMA, MDA, lysine-conjugated MDMA (lysine-MDMA), lysine-conjugated MDA (lysine-MDA), and placebo in healthy volunteers. The primary hypotheses were that MDA would show a longer plasma half-life and longer-lasting, more psychedelic-like perceptual effects than MDMA, and that lysine conjugation would delay onset and peak concentrations and associated effects, producing a slow-release profile that might attenuate rapid-onset euphoria and adverse effects.

The study used a double-blind, placebo-controlled, crossover design with five 13-hour test sessions per participant: placebo, 100 mg MDMA, 92 mg MDA, 172 mg lysine-MDMA, and 164 mg lysine-MDA (mole-equivalent doses). Twenty-three healthy participants (12 women, 11 men; mean age 29 ± 9 years, range 20–51) completed all sessions. Block randomization produced counterbalanced treatment orders and washouts of at least 14 days (mean interval between sessions 42 ± 11 days). Sessions took place in a calm hospital room with one participant and one investigator; substances were administered at 09:00 and participants remained under observation for repeated assessments up to 12 hours, with follow-up at 24 hours. Subjective outcomes included repeated Visual Analog Scales (VAS) from 0.5 h before to 24 h after dosing, the Adjective Mood Rating Scale (AMRS) at selected post-dose times, the 5-Dimensions of Altered States of Consciousness (5D-ASC) and the Psychedelic Experience Scale (PES) at 12 h. Autonomic measures (blood pressure, heart rate, tympanic temperature, pupil size) and ECG (QTc) were recorded at the same time points as the VAS. Endocrine assays measured plasma oxytocin at baseline and 2, 3, and 6 h; neurophysin I (a carrier protein and proxy for oxytocin activation) was assayed for MDMA, MDA and placebo conditions. Plasma concentrations of MDMA, MDA and metabolites (HMMA, HMA) were quantified by HPLC–MS and pharmacokinetic parameters estimated with non-compartmental methods (Phoenix WinNonlin). The original plan specified a nested 2 × 2 factorial analysis (drug type × lysine conjugation), but because lysine-MDMA produced no detectable MDMA or effects, the design was altered. Repeated-measures ANOVAs assessed main condition effects; predefined pairwise contrasts compared five specific contrasts (placebo vs lysine-MDMA, placebo vs MDMA, placebo vs MDA, MDMA vs MDA, MDA vs lysine-MDA) with Holm-adjusted p values for multiplicity. Additional post-hoc contrasts were Tukey-adjusted. Sex-by-condition interactions were explored by including sex as a between-subjects factor. Effect sizes were reported as Cohen's d for within-subject comparisons and partial eta-squared for ANOVAs. Blinding was assessed by asking participants to guess their treatment after sessions. All analyses were performed in R, with significance set at p < 0.05.

Subjective effects: MDA produced larger and longer-lasting subjective drug effects than MDMA. Mean effect durations for the VAS item “any drug effect” were 6.1 ± 0.5 h for MDA versus 4.1 ± 0.4 h for MDMA. Compared with MDMA, MDA elicited greater VAS ratings of stimulation, negative "bad drug effects," fear, and "alteration of vision." On the PES48, MDA produced significantly higher ratings for "distressing experience" and nominally higher "visual experience;" the 5D-ASC showed nominal (non-significant) increases in complex and elementary imagery for MDA. AMRS scores indicated more emotional excitation after MDA. Both MDMA and MDA reached peak effects around 2 h post-dose, but MDA’s duration was approximately 2 h longer. Lysine-conjugates: Lysine-MDA (referred to in the paper as Lys-MDA) behaved as a slow-release prodrug of MDA: no parent–drug classification ambiguity was reported and pharmacokinetics and subjective/autonomic effects were delayed relative to MDA. Time to onset of subjective effect was 1.1 ± 0.2 h for lysine-MDA versus 0.7 ± 0.1 h for MDA; time to maximal effect was 3.0 ± 0.4 h versus 2.0 ± 0.1 h. Maximal MDA concentrations were slightly lower after lysine-MDA (geometric mean Cmax 207 ng/ml) than after MDA (231 ng/ml). In contrast, lysine-MDMA was pharmacologically inactive: no MDMA was detectable in plasma after lysine-MDMA administration and no subjective or autonomic effects were observed; participants misclassified lysine-MDMA as placebo in 65% of sessions. Autonomic, endocrine and safety findings: MDMA, MDA and lysine-MDA produced comparable increases in blood pressure, heart rate, tympanic temperature and pupil diameter compared with placebo, though MDA and lysine-MDA effects were longer-lasting than MDMA. Lysine-MDMA produced no autonomic changes. No drug altered QTc intervals. MDMA, MDA and lysine-MDA all increased plasma oxytocin relative to placebo; lysine-MDA’s oxytocin rise was delayed versus MDA. Neurophysin I increased markedly after MDMA and MDA (neurophysin measured only for MDMA, MDA and placebo) and correlated strongly with oxytocin (Pearson r = 0.82, p < 0.001), with each 1000 pg/ml rise in neurophysin I corresponding to a 28 pg/ml increase in oxytocin. Adverse effects and modifiers: MDA and lysine-MDA were associated with more acute and subacute adverse effects on the List of Complaints than MDMA; frequently reported subacute complaints included headache, lack of energy, appetite loss, increased need to sleep and exhaustion. Female participants reported more acute and subacute adverse effects after MDA and lysine-MDA than males. CYP2D6 poor metabolizers (PMs) had longer elimination half-lives and greater AUC for MDMA and MDA and reported more subacute adverse effects than intermediate and extensive metabolizers; genotype differences also affected metabolite (HMMA, HMA) exposure. Pharmacokinetics: geometric mean elimination half-lives were 7.3 h for MDMA, 8.4 h for MDA, and 7.9 h for MDA after lysine-MDA. Times to maximal concentration were approximately 3.0 h (MDMA), 3.4 h (MDA), and 3.8 h (MDA after lysine-MDA). Blinding and placebo effects: participants could not reliably distinguish MDMA, MDA and lysine-MDA; 74% correctly identified placebo sessions. The unexpected pharmacological inertness of lysine-MDMA produced a second, unanticipated placebo session, during which subjective ratings were higher than during the first placebo session, consistent with expectancy effects.

Straumann and colleagues interpret their findings as the first within-subject demonstration that MDA produces longer-lasting and, in several domains, stronger acute subjective effects than equimolar MDMA. They attribute the longer duration primarily to MDA’s longer plasma elimination half-life and the greater stimulant and perceptual effects to MDA’s relatively higher dopaminergic activity and substantially greater 5-HT2A agonist potency. Although MDA increased oxytocin and neurophysin I as much as or more than MDMA—suggesting shared prosocial effects that could theoretically be relevant to therapy—the study found that MDA also produced more negative acute experiences (fear, distress) and more subacute complaints, indicating a narrower therapeutic margin compared with MDMA. The lysine prodrug approach yielded mixed results. Lysine-MDA functioned as a functional slow-release prodrug, delaying onset and peak subjective and autonomic effects and delaying oxytocin release, while producing comparable maximal effects to MDA; the authors propose lysine conjugation as a possible strategy to modify time course. By contrast, lysine-MDMA failed to release MDMA, likely because its tertiary amine structure prevents conversion by plasma peptidases, so it did not serve as an effective prodrug and effectively acted as a second placebo. The unexpected second placebo session revealed an expectancy effect: later-occurring placebo sessions elicited higher early-session subjective ratings, underscoring the importance of accounting for expectancy in within-subject psychedelic studies. The authors note strengths including the within-subject randomized double-blind design, a relatively large sample for such pharmacology work (n = 23), dense PK sampling and a broad set of validated psychometric measures. Key limitations acknowledged are the inability to implement the original factorial statistical plan because lysine-MDMA was inactive, assessment at a single dose level using racemic mixtures, the healthy-volunteer sample limiting generalisability to patient populations, and the potential for repeated dosing to alter pharmacokinetics or risk toxicity and dependence. The investigators also caution that some subtle experiential differences might not have been captured by the selected outcome measures. Finally, CYP2D6 genotype affected PK and subacute tolerability but did not map onto acute subjective differences in this sample.

MDA produced longer-lasting, stronger subjective effects than equimolar MDMA, including greater stimulation, more negative "bad drug effects" and more psychedelic-like perceptual alterations, and it was associated with more acute and subacute adverse effects. Lysine-MDA acted as a functional slow-release prodrug of MDA by delaying onset and peak effects, whereas lysine-MDMA did not release MDMA and was pharmacologically inactive. Overall, the results indicate a narrower therapeutic margin for MDA compared with MDMA and suggest that lysine conjugation can alter the time course of amphetamine-like substances, though not necessarily improve overall tolerability.